PGRN Committees And Groups
PGRN welcomes all members to participate in the future direction of the society by joining a committee, interest group, or working group. If you have any questions, please contact info@pgrn.org
Scientific Committee
Mission Statement: To develop scientific programming for the annual meeting and other programs as needed. Vice Chair: Daniel Hertz Julie Johnson |
Communications Committee
Mission Statement: To increase the visibility and growth of the PGRN in the scientific and medical communities, through social media and media sharing networks, blogs, pgrn.org and other potential networking opportunities. Chair: Assaf Gottlieb Members: |
Global PGx Committee
Mission Statement: To serve to stimulate research, education and practice of PGx. This will be done through building capacity for PGx research, promoting research through fostering networking, building critical mass of PGx knowledgeable communities through educational programs and creating stakeholder awareness through advocacy. Vice Chair: Mohamed Nagy Andrew Monte |
Early Career Committee
Mission Statement: To facilitate engagement and visibility of trainees and early career scientists in the field of pharmacogenomics and to develop programs that will enhance the careers of these trainees and early career scientists. Chair: Aniwaa Owusu Obeng
Members: Sonali Deore |
Education Committee
Mission Statement: The education committee will develop PGRN educational programs and content focused on research and clinical implementation of PGx for trainees, researchers, practitioners and the public. Chair: Phil Empey Members: Kateryna Petrykey |
Publications Committee
Mission: To promote the field of pharmacogenomics within the global scientific and clinical communities through written publications. This will be accomplished by writing and submitting manuscripts (e.g., commentaries, guidelines, positions papers, reviews, meeting reviews) on all aspects of pharmacogenomics ranging from discovery through implementation, and sponsoring theme issues in scientific journals including pharmacology, medical, and other journals. Publications Committee Chair: Akin Oni-Orisan Michelle Whirl-Carrillo
|
Psychiatry Interest Group
The “Pharmacogenetics in Psychiatry Interest Group (PPIG)” has evolved as a sub-group with support from the Pharmacogenomic Global Research Network (PGRN) leadership. Established in March 2021, the PPIG meets every two months and aims to bring together scientists from all over the world, working in academia and industry, interested in the exciting and emerging field of Psychiatric Pharmacogenomics. Through our virtual meetings, we will discuss and disseminate ongoing and prospective research related to the implementation of PGx into the psychiatric clinical practice, including cost reimbursement and electronic health record opportunities. Given the diverse nature of our group, researchers have the opportunity to drive different healthcare systems and regimes, learn, adopt strategies that fit their organizations and be better prepared to act as implementers. Moreover, group members will actively engage in networking and assist early career researchers in their career planning and facilitate contacts to senior researchers in Psychiatric PGx. Educational and knowledge translation activities are organized in conjunction with PGRN and linked to larger conferences where in-person meetings are organized. The group is committed to promoting and addressing equity, diversity, and inclusion in research and clinical practice. As the group evolves, we will seek publication and funding opportunities to achieve maximum output through joint efforts. To serve our purpose, we welcome new members and volunteers from across the globe to join our meetings, especially from developing countries, and help in the organization and curation of our group efforts. Daniel Mueller | PSYCHIATRY INTEREST GROUP SEMINAR The Psychiatry Special Interest Group is delighted to present periodic zoom seminars at our regular Psychiatry SIG meetings. Presentations feature leading researchers at the intersection of PGx and psychiatry and allow ample time for discussion. The details of our most recent seminar can be found on the Webinars And Meetings page. |
Oncology Interest Group (Collaborative Cancer PGx Research)
The purpose of CPR subcommittee is to facilitate opportunities to i) enhance collaborative research among members of the PGRN Oncology SIG and ii) generate high impact research outputs (e.g. publications, grants) for members of this group. Our 1-year goals are to: 1. Create a repository of previously published data (e.g. GWAS summary statistics) 2. Create a searchable database of PGx oncology cohorts that are available through the SIG to facilitate collaboration between researchers focusing on similar PGx traits, which will results in successful PGRN grant(s) 3. Explore opportunities to integrate PGx research into already existing cancer genetics projects (e.g. CONFLUENCE project) Our 5-year goals are to: 1. Publish articles from research performed using data housed in the repository 2. Generate collaborative research outputs that are enabled through the use of the searchable database. This includes submission of grants to major funding agencies (e.g. NIH), which include pilot data generated using funds from successful PGRN grant(s). 3. Demonstrate how PGx can be integrated into large-scale cancer projects and identify additional large-scale resources where PGx can be integrated Lead: Britt Drogemoller Leadership Team: Eileen Dolan |
Oncology Interest Group (Clinical PGx Implementation)
The purpose of the Clinical PGx Implementation subcommittee is to i) serve as hub to connect oncology PGx practitioners and ii) to allow oncology PGx practitioners to seek and exchange implementation successes and challenges, Our 1-year goals are to: 1. Introduce the PGRN Onc SIG to the oncology implementers in the pharmacogenomics community 2. Understand the current state of clinical gene/drug pair implementations at oncology sites 3. Create a searchable database of pharmacogenomics practitioners to facilitate the discussion and exchange of oncology PGx implementation experience Our 5-year goals are to: 1. Publish articles highlighting unique implementation aspects at oncology PGx sites 2. Establish a network of oncology pharmacogenomics practitioners 3. Serve as the main forum for PGx oncology practitioners for implementation data sharing and collaboration (for example, with IGNITE) Lead: Cyrine Haidar Leadership Team: Cyrine Haidar |
PGRN Implementation Working Group
The PGRN Implementation Working Group provides a venue for members to collaborate on implementation research and to advance the field of clinical pharmacogenetics. Purpose: The goal of the group is to share and collectively publish information on pharmacogenetics implementation priorities, strategies, metrics, and health-related outcomes associated with the use of pharmacogenetic information for clinical care. The ultimate goal is to advance pharmacogenetic testing, and through that improve drug related outcomes globally. Opportunities: With its global membership, the PGRN enables multi-site studies of pharmacogenetic implementation on an international level, thereby increase the diversity of the populations included in studies in studies of pharmacogenetic testing and generalizability of the data. Membership: The working group is open to all PGRN members who have implemented pharmacogenetic testing in practice or have interest in implementing testing. Meetings: The group will meet twice monthly to discuss new project ideas and to provide updates on on-going projects. Stay tuned for the meeting schedule. Interested in joining? All interested members are encouraged to contact Griffin Peters at griffin@pgrn.org. We are happy to announce that we have scheduled the new PGRN Implementation Calls to take place on the first and third Wednesdays of the month at 11 AM Eastern time. This group’s first call will take place next Wednesday, September 20th at 11 AM ET. Please note that you need to be a PGRN Member to take part in this initiative. PGRN Implementation Working Group - Collaborative Agreement |